Literature DB >> 27726247

MRI assessment of pathological stage and surgical margins in anterior prostate cancer (APC) using subjective and quantitative analysis.

Nicola Schieda1, Christopher S Lim1, Muhammad Idris1, Robert S Lim1, Christopher Morash2, Rodney H Breau2, Trevor A Flood3, Matthew D F McInnes1.   

Abstract

PURPOSE: To evaluate magnetic resonance imaging (MRI) for assessment of extraprostatic extension (EPE) and positive surgical margins (PSM) in anterior prostate cancer (APC).
MATERIALS AND METHODS: With Institutional Review Board approval, 25 APC (>2/3 of tumor anterior to urethra) were assessed using 3T MRI by two blinded radiologists for: size and maximal leading edge of tumor (relative to anterior fibromuscular stroma [AFMS]) on b ≥1000 sec/mm2 echo-planar-MRI fused onto T2 -weighted-MRI, invasion of AFMS and EPE. Comparisons were performed between APCs by EPE/PSM using chi-square, multivariable analysis, and receiver operator characteristic (ROC) analysis.
RESULTS: The prevalence of EPE and PSM were 52% (13/25) and 36% (9/25). Tumor sizes were larger with EPE (22.5 ± 8.4 vs. 14.7 ± 6.3, P = 0.02) and PSM (23.0 ± 9.3 vs. 16.4 ± 7.0, P = 0.06). Area under ROC curve (AUC-ROC) for the diagnosis of EPE by tumor size was 0.77 (95% confidence interval [CI] 0.58-0.95); ≥16 mm size = sensitivity/specificity 69.2/66.7%. Maximal leading edge of tumor was greater with EPE (2.4 ± 2.2 vs. -0.2 ± 3.0) and PSM (2.8 ± 2.3 vs. -0.3 ± 2.5), (P = 0.023, 0.031). AUC-ROC for diagnosis of EPE/PSM by leading edge was 0.78 (CI 0.57-0.97) and 0.75 (CI 0.56-0.94). A ≥1 mm leading edge yielded sensitivity/specificity of 76.9/75.0% and 77.8/62.5% for diagnosis of EPE/PSM. 60-72% (15-18/25) tumors invaded AFMS (k = 0.74), which was not associated with EPE/PSM (P = 0.12-0.14). Radiologists' assessment of EPE had sensitivity/specificity of 61.5-69.2/50.0-75.0% (k = 0.53).
CONCLUSION: Tumor size and leading edge of tumor relative to AFMS may enable diagnosis of EPE and positive surgical margins in APC. LEVEL OF EVIDENCE: 2 J. MAGN. RESON. IMAGING 2017;45:1296-1303.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  MRI; anterior; extraprostatic extension; prostate cancer; surgical margin

Mesh:

Substances:

Year:  2016        PMID: 27726247     DOI: 10.1002/jmri.25510

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Prediction of extraprostatic extension on multi-parametric magnetic resonance imaging in patients with anterior prostate cancer.

Authors:  Hyungwoo Ahn; Sung Il Hwang; Hak Jong Lee; Hyoung Sim Suh; Gheeyoung Choe; Seok-Soo Byun; Sung Kyu Hong; Sangchul Lee; Joongyub Lee
Journal:  Eur Radiol       Date:  2019-08-05       Impact factor: 5.315

2.  Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.

Authors:  Jorge Abreu-Gomez; Daniel Walker; Tareq Alotaibi; Matthew D F McInnes; Trevor A Flood; Nicola Schieda
Journal:  Eur Radiol       Date:  2020-03-24       Impact factor: 5.315

3.  Prediction of Response to Neoadjuvant Chemoradiotherapy by MRI-Based Machine Learning Texture Analysis in Rectal Cancer Patients.

Authors:  Sajad P Shayesteh; Afsaneh Alikhassi; Farshid Farhan; Reza Ghalehtaki; Masume Soltanabadi; Peiman Haddad; Ahmad Bitarafan-Rajabi
Journal:  J Gastrointest Cancer       Date:  2020-06

4.  The Quantitative Assessment of Using Multiparametric MRI for Prediction of Extraprostatic Extension in Patients Undergoing Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Authors:  Wei Li; Yuan Sun; Yiman Wu; Feng Lu; Hongtao Xu
Journal:  Front Oncol       Date:  2021-11-22       Impact factor: 6.244

5.  Diagnostic Performance of Extraprostatic Extension Grading System for Detection of Extraprostatic Extension in Prostate Cancer: A Diagnostic Systematic Review and Meta-Analysis.

Authors:  Wei Li; Wenwen Shang; Feng Lu; Yuan Sun; Jun Tian; Yiman Wu; Anding Dong
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.